Hints and tips:
Related Special Reports
...For all companies facing the new Medicare regime, much rides on drug discovery. The best-placed companies can buy or build highly prized new medicines. US reforms will put Big Pharma under pressure....
...BMS, which last week posted better than expected earnings from treatments such as anaemia drug Reblozyl and heart medicine Camzyos, has previously delayed by a year, to 2026, when it expects the new product...
...The head of Google DeepMind believes its drug discovery spinout will halve the time taken to find new medicines, attracting the attention of the world’s biggest pharmaceutical companies which are looking...
...Under the proposed reforms, Medicare, the US taxpayer-funded healthcare scheme for retirees, would be allowed to negotiate prices for a limited number of branded medicines....
...Under the reforms, Medicare, the US taxpayer-funded healthcare scheme for retirees, is allowed to negotiate prices for a limited number of branded medicines....
...clot prevention medicine from Bayer and the Johnson & Johnson subsidiary Janssen Pharmaceuticals....
...Bristol Myers Squibb; and a Novartis drug to treat heart failure called Entresto....
...Bristol Myers Squibb told the FT last year it expected to cancel some drug programmes, with cancer medicines most vulnerable....
...medicines....
...It follows similar lawsuits filed in recent weeks by Merck and Bristol Myers Squibb....
...Bristol-Myers Squibb earlier this month agreed to buy Turning Point Therapeutics, which is developing a new cancer drug, for $4.1bn....
...The IDA said this trend was benefiting Ireland, which manufactures everything from drug ingredients to tablets and more complex biological medicines....
...GSK, Pfizer and Bristol Myers Squibb were among other big pharmaceutical companies that stopped trying to find treatments for some of humanity’s most inscrutable diseases....
...Bristol Myers Squibb says it expects to cancel some drug development programmes due to US government drug pricing rules that are due to be phased in from next year....
...But he added that these were not matched by marketplace dynamics that enabled drug companies like Bristol Myers Squibb to recover their substantial spending on research and development in developing life-saving...
...Users such as Cox don’t consider it to be “drugs” but “medicine”. “It’s not recreational,” he points out. “It is deep, healing, transformative work....
...since the medicine was launched....
...Critics allege the strategy delays the launch of generic medicines by rivals even after the 20-year exclusivity period on the primary patents of blockbuster drugs elapses....
...Last year, US drugmaker Bristol Myers Squibb said it could divert investment away from the UK because of the increasing clawbacks....
...The chief executive of Bristol Myers Squibb said last week he had a “significant concern” about the rising costs of a medicines levy, agreed between government and industry to cap the health service drugs...
...Bristol Myers Squibb said last month that the expansion of the UK’s voluntary scheme for branded medicines pricing and access could divert investment away from the country....
...Trapp spends almost $20,000 a year in “out of pocket” costs on Revlimid, a cancer therapy developed by Celgene, which was acquired by Bristol Myers Squibb in 2019....
...Then, we hear about a new trend in drug research. Scientists can now grow entire human mini-organs in labs. Could that lead to a world without animal testing?...
International Edition